Novartis AG (NYSE:NVS - Free Report) - Analysts at Zacks Research decreased their Q4 2024 EPS estimates for Novartis in a research note issued to investors on Tuesday, November 12th. Zacks Research analyst E. Bagri now expects that the company will post earnings of $1.76 per share for the quarter, down from their previous forecast of $1.86. The consensus estimate for Novartis' current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis' Q3 2025 earnings at $2.18 EPS, Q4 2025 earnings at $2.02 EPS, FY2025 earnings at $8.23 EPS, Q2 2026 earnings at $2.22 EPS and Q3 2026 earnings at $2.42 EPS.
Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the prior year, the business posted $1.74 earnings per share.
A number of other equities analysts have also commented on the stock. The Goldman Sachs Group reissued a "neutral" rating and issued a $121.00 price target (up previously from $119.00) on shares of Novartis in a research report on Thursday, September 5th. Jefferies Financial Group downgraded Novartis from a "buy" rating to a "hold" rating in a research report on Tuesday, September 3rd. Bank of America cut Novartis from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $135.00 to $130.00 in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Novartis in a report on Friday, July 19th. Finally, BMO Capital Markets upped their price target on Novartis from $118.00 to $120.00 and gave the stock a "market perform" rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $121.50.
View Our Latest Stock Report on Novartis
Novartis Stock Performance
Shares of NVS stock traded down $0.34 during trading on Friday, reaching $103.06. The company had a trading volume of 1,452,229 shares, compared to its average volume of 1,345,274. The firm's 50 day simple moving average is $113.41 and its two-hundred day simple moving average is $109.79. Novartis has a one year low of $92.35 and a one year high of $120.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The company has a market capitalization of $210.65 billion, a PE ratio of 11.93, a PEG ratio of 1.50 and a beta of 0.58.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James & Associates lifted its position in shares of Novartis by 1.3% during the 2nd quarter. Raymond James & Associates now owns 536,607 shares of the company's stock worth $57,127,000 after buying an additional 6,767 shares during the period. Manning & Napier Advisors LLC acquired a new stake in shares of Novartis in the 2nd quarter valued at $15,044,000. O Shaughnessy Asset Management LLC grew its holdings in shares of Novartis by 6.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 180,764 shares of the company's stock worth $17,485,000 after purchasing an additional 11,080 shares during the last quarter. Integral Health Asset Management LLC increased its position in shares of Novartis by 33.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company's stock worth $31,938,000 after purchasing an additional 75,000 shares in the last quarter. Finally, Granite Bay Wealth Management LLC bought a new position in Novartis during the 2nd quarter valued at about $854,000. Institutional investors own 13.12% of the company's stock.
About Novartis
(
Get Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Stories
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
